… was valsartan, whereas enalapril was the active treatment comparator in the PARADIGM-HF
trial. Although angiotensin-converting enzyme inhibitors and angiotensin receptor blockers …

… Sacubitril-valsartan has been shown to … angiotensin receptor blockers in patients with heart
failure (HF) and hypertension. The efficacy and safety of sacubitril-valsartan in patients with …

… in-class angiotensin receptor neprilysin inhibitor (ARNI… study, we systematically analyzed
the available studies investigating the effects of sacubitril/valsartan in patients with heart failure …

… enzyme inhibitor (ACEI), an angiotensin receptor blocker (… of angiotensin receptor neprilysin
inhibitor (ARNi) on cardiac status compared to valsartan in patients with chronic heart failure …

… enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), … trial using the combined
angiotensin receptor–neprilysin … 160 mg twice daily in a phase 2 randomized trial of 266 patients…

… In the present study, treatment with the maximal tolerated dose of valsartan did not exhibit
a superior effect on post-MI LV remodelling compared with low-dose treatment and was …

… or hospitalization for heart failure in the patients with both … -analyses of randomized trials
in patients with HFrEF that compared … of cardiovascular mortality and worsening heart failure. …

… (LCZ696) is superior to angiotensin receptor blocker (ARB) monotherapy for reducing …
PARAMETER study is a multicenter, double-blind, randomized trial with sacubitril/valsartan (…

… /valsartan might be beneficial in a wider population of patients with heart failure than the …
These new types of drugs are classified as angiotensin receptor blocker neprilysin inhibitors …

… for ACE inhibitors/angiotensin receptor blockers (ARBs) in patients with symptomatic HFrEF.
… was a multicenter randomized trial conducted at 85 hospital and clinic-based study sites in …